Your browser doesn't support javascript.
CHARM: COVID-19 Health Action Response for Marines-Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test.
Sedegah, Martha; Porter, Chad; Hollingdale, Michael R; Ganeshan, Harini; Huang, Jun; Goforth, Carl W; Belmonte, Maria; Belmonte, Arnel; Weir, Dawn L; Lizewski, Rhonda A; Lizewski, Stephen E; Sealfon, Stuart C; Jani, Vihasi; Cheng, Ying; Inoue, Sandra; Velasco, Rachael; Villasante, Eileen; Sun, Peifang; Letizia, Andrew G.
  • Sedegah M; Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Porter C; Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Hollingdale MR; Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Ganeshan H; Henry M. Jackson Foundation, Bethesda, MD, United States of America.
  • Huang J; Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Goforth CW; Henry M. Jackson Foundation, Bethesda, MD, United States of America.
  • Belmonte M; Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Belmonte A; Henry M. Jackson Foundation, Bethesda, MD, United States of America.
  • Weir DL; Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Lizewski RA; Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Lizewski SE; Henry M. Jackson Foundation, Bethesda, MD, United States of America.
  • Sealfon SC; Agile Vaccines and Therapeutics Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Jani V; GDIT, MD, United States of America.
  • Cheng Y; Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Inoue S; U.S. Naval Medical Research Unit SIX, Lima, Perú.
  • Velasco R; U.S. Naval Medical Research Unit SIX, Lima, Perú.
  • Villasante E; Icahn School of Medicine at Mount Sinai, New York, NY, United States of America.
  • Sun P; Virology Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Letizia AG; Henry M. Jackson Foundation, Bethesda, MD, United States of America.
PLoS One ; 17(4): e0266691, 2022.
Article in English | MEDLINE | ID: covidwho-1779779
ABSTRACT
SARS-CoV-2 T cell responses are associated with COVID-19 recovery, and Class I- and Class II-restricted epitopes have been identified in the spike (S), nucleocapsid (N) and membrane (M) proteins and others. This prospective COVID-19 Health Action Response for Marines (CHARM) study enabled assessment of T cell responses against S, N and M proteins in symptomatic and asymptomatic SARS-CoV-2 infected participants. At enrollment all participants were negative by qPCR; follow-up occurred biweekly and bimonthly for the next 6 weeks. Study participants who tested positive by qPCR SARS-CoV-2 test were enrolled in an immune response sub-study. FluoroSpot interferon-gamma (IFN-γ) and IL2 responses following qPCR-confirmed infection at enrollment (day 0), day 7 and 14 and more than 28 days later were measured using pools of 17mer peptides covering S, N, and M proteins, or CD4+CD8 peptide pools containing predicted epitopes from multiple SARS-CoV-2 antigens. Among 124 asymptomatic and 105 symptomatic participants, SARS-CoV-2 infection generated IFN-γ responses to the S, N and M proteins that persisted longer in asymptomatic cases. IFN-γ responses were significantly (p = 0.001) more frequent to the N pool (51.4%) than the M pool (18.9%) among asymptomatic but not symptomatic subjects. Asymptomatic IFN-γ responders to the CD4+CD8 pool responded more frequently to the S pool (55.6%) and N pool (57.1%), than the M pool (7.1%), but not symptomatic participants. The frequencies of IFN-γ responses to the S and N+M pools peaked 7 days after the positive qPCR test among asymptomatic (S pool 22.2%; N+M pool 28.7%) and symptomatic (S pool 15.3%; N+M pool 21.9%) participants and dropped by >28 days. Magnitudes of post-infection IFN-γ and IL2 responses to the N+M pool were significantly correlated with IFN-γ and IL2 responses to the N and M pools. These data further support the central role of Th1-biased cell mediated immunity IFN-γ and IL2 responses, particularly to the N protein, in controlling COVID-19 symptoms, and justify T cell-based COVID-19 vaccines that include the N and S proteins.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon-gamma / Interleukin-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0266691

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon-gamma / Interleukin-2 / COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0266691